GRI Bio Stock (NASDAQ:GRI)

Financials Chart

Previous Close

$2.05

52W Range

$1.10 - $22.95

50D Avg

$1.80

200D Avg

$3.52

Market Cap

$5.08M

Avg Vol (3M)

$1.21M

Beta

-1.44

Div Yield

GRI Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 10, 2021

Website

GRI Performance

GRI Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-8.23M	$-11.39M	$-2.24M
Net Income	$-8.21M	$-13.04M	$-3.22M
EBITDA	$-8.23M	$-10.90M	$-2.51M
Basic EPS	$-55.21	$-6.24K	$-165.35K
Diluted EPS	$-55.21	$-6.24K	$-165.35K

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
JAGX	Jaguar Health, Inc.
OCEA	Ocean Biomedical, Inc.
LEXX	Lexaria Bioscience Corp.
WINT	Windtree Therapeutics, Inc.
SILO	Silo Pharma, Inc.
INM	InMed Pharmaceuticals Inc.
CNSP	CNS Pharmaceuticals, Inc.
CMND	Clearmind Medicine Inc.